| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPLUNC3 |
| Uniprot No | Q9BQP9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-254aa |
| 氨基酸序列 | MMCPLWRLLIFLGLLALPLAPHKQPWPGLAQAHRDNKSTLARIIAQGLIKHNAESRIQNIHFGDRLNASAQVAPGLVGWLISGRKHQQQQESSINITNIQLDCGGIQISFHKEWFSANISLEFDLELRPSFDNNIVKMCAHMSIVVEFWLEKDEFGRRDLVIGKCDAEPSSVHVAILTEAIPPKMNQFLYNLKENLQKVLPHMVESQVCPLIGEILGQLDVKLLKSLIEQEAAHEPTHHETSQPSACQAGESPS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SPLUNC3重组蛋白的3篇模拟参考文献示例(注：部分信息为示例性概括，实际文献需通过数据库查询)：
1. **文献名称**：*"Recombinant SPLUNC3 exhibits antimicrobial activity in airway epithelial cells"*
**作者**：Chu, H.W. et al.
**摘要**：研究利用大肠杆菌系统表达重组人SPLUNC3蛋白，证实其在体外对铜绿假单胞菌的抑菌作用，并揭示其通过破坏细菌膜完整性发挥功能。
2. **文献名称**：*"Structural characterization of SPLUNC3 and its role in innate immunity"*
**作者**：Bingle, L. et al.
**摘要**：通过X射线晶体学解析SPLUNC3重组蛋白的三维结构，发现其具有典型BPI折叠结构域，并证明其与脂多糖(LPS)结合能力，提示其在调节炎症反应中的作用。
3. **文献名称**：*"SPLUNC3 modulates TLR4 signaling pathway in pulmonary inflammation"*
**作者**：Liu, Y. et al.
**摘要**：研究发现重组SPLUNC3蛋白可通过抑制TLR4/NF-κB信号通路减轻小鼠模型中的急性肺损伤，表明其作为潜在抗炎治疗分子的可能性。
(提示：实际文献检索推荐使用PubMed或Google Scholar，以"SPLUNC3 recombinant protein"为关键词查询最新研究进展)
SPLUNC3 (Short Palate, Lung, and Nasal Epithelium Clone 3) is a member of the BPI (bactericidal/permeability-increasing protein)/PLUNC (palate, lung, and nasal epithelium clone) family, a group of secreted proteins predominantly expressed in mucosal surfaces of the respiratory and oral cavities. These proteins are evolutionarily conserved and play roles in innate immunity, inflammation modulation, and microbial defense. SPLUNC3. encoded by the *SPLUNC3* gene in humans, is characterized by its structural homology to lipid-binding proteins, particularly the BRICHOS domain, which is associated with chaperone-like functions and anti-inflammatory properties. It is primarily produced in epithelial tissues of the upper airways, salivary glands, and oral mucosa, suggesting its involvement in maintaining mucosal homeostasis.
Research indicates that SPLUNC3 contributes to host defense by interacting with pathogens, regulating immune responses, and modulating surfactant composition. Unlike its well-studied paralog SPLUNC1. which is linked to airway hydration and antimicrobial activity, SPLUNC3’s exact mechanistic roles remain less defined. Studies suggest it may bind lipid components of bacterial membranes or host-derived molecules, influencing inflammatory signaling pathways such as NF-κB. Its recombinant form, generated via expression systems like *E. coli* or mammalian cells, enables functional and structural studies. Recombinant SPLUNC3 is utilized to explore its therapeutic potential in conditions like chronic obstructive pulmonary disease (COPD), cystic fibrosis, or periodontitis, where mucosal immunity is compromised.
Despite progress, key questions persist regarding its physiological ligands, tissue-specific isoforms, and interactions with microbial communities. Ongoing research aims to clarify its dual role in protection and inflammation, leveraging recombinant protein tools to advance diagnostic or therapeutic strategies for mucosal diseases.
×
